Discovery and development of clofarabine: a nucleoside analogue for treating cancer
| Autor: | Larry Arthaud, Steven D. Weitman, Peter L. Bonate, William R. Cantrell, Katherine Stephenson, John A. Secrist |
|---|---|
| Rok vydání: | 2006 |
| Předmět: |
Drug
medicine.medical_specialty media_common.quotation_subject Antineoplastic Agents Neoplasms Drug Discovery Humans Medicine Clofarabine Intensive care medicine Drug Approval Complete response media_common Paediatric patients Pharmacology Clinical Trials as Topic Nucleoside analogue Adenine Nucleotides business.industry Complete remission Cancer General Medicine Acute leukaemias Precursor Cell Lymphoblastic Leukemia-Lymphoma medicine.disease Leukemia Myeloid Acute Drug Design Arabinonucleosides business medicine.drug |
| Zdroj: | Nature Reviews Drug Discovery. 5:855-863 |
| ISSN: | 1474-1784 1474-1776 |
| DOI: | 10.1038/nrd2055 |
| Popis: | Despite considerable progress in the treatment of paediatric leukaemias, a major need still exists for therapies for patients who relapse. Bonate and colleagues describe the discovery and development of the nucleoside analogue clofarabine, which is the first such drug approved for paediatric leukaemia in more than a decade, and the first to receive approval for paediatric use before adult use. The treatment of acute leukaemias, which are the most common paediatric cancers, has improved considerably in recent decades, with complete response rates approaching ∼90% in some cases. However, there remains a major need for treatments for patients who do not achieve or maintain complete remission, for whom the prognosis is very poor. In this article, we describe the challenges involved in the discovery and development of clofarabine, a second-generation nucleoside analogue that received accelerated approval from the US FDA at the end of 2004 for the treatment of paediatric patients 1–21 years old with relapsed or refractory acute lymphoblastic leukaemia after at least two prior regimens. It is the first such drug to be approved for paediatric leukaemia in more than a decade, and the first to receive approval for paediatric use before adult use. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|